- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Why Study the Studies of PDTs?
Prescription digital therapeutics (PDTs) have great potential for treating a wide range of conditions, so studying the quality of the evidence supporting their efficacy and safety is important, says the corresponding author of a study on PDTS published in this month's Health Affairs.
Sanket S. Dhruva, M.D., M.H.S., an assistant professor at the University of California, San Francisco, discusses the reasons he and his colleagues set out to examine the research supporting prescription digital therapeutics (PDTs) and the challenge of finding all the studies related to the 20 PDTs they focused on.
Prescription digital therapeutics “have tremendous potential to help diagnose and treat important health conditions that affect patients both in the United State and worldwide,” said Dhruva.
But Dhruva said that as far as he and his colleagues know, an evaluation of the evidence for PDTs has not been done.
"We wanted to know what is the quality of the evidence supporting prescription digital therapeutics," he said.
Although PDTs are a small subset of all the digital therapeutics, Dhruva said "we would expect these to be the cream of crop in terms of the quality of the evidence, because they received FDA authorization."
PDT Studies: The Positives, the Shortcomings — and Getting the Good Parts ‘Packaged Together’
November 17th 2023The corresponding author of a study published in Health Affairs of the research supporting 20 FDA-authorized prescription digital therapeutics (PDTs) sees some positives but also an overall lack of rigor and the need for at least one high-quality clinical trial for each PDT.
Read More
Studies Supporting PDTs Often Short on Rigor, Inclusivity, Research Finds
November 16th 2023There were some positive findings. But of the 20 FDA-authorized prescription digital therapeutics (PDTs) identified by researchers, only two met all the criteria for high-quality research. The results were published in Health Affairs.
Read More
Internet-based CBT Helps MS Patients With Depression Become Less Depressed
October 24th 2023Results of a randomized trial reported in The Lancet Digital Health suggest a role for internet-based cognitive behavioral therapy, but many of the study volunteers were left with symptoms that would classify them as having major depressive disorder.
Read More
The Challenges and Opportunities of At-Home Phototherapy
October 24th 2023Lisa Rometty, CEO at Zerigo Health, discusses the challenges and opportunities for growth within the digital health landscape, as well as how Zerigo plans to collaborate with patients and payers to make sure digital health tools are accessible and affordable.
Read More
